A new combination therapy may help the immune system better attack cancer

'This may be a huge advantage because we can systematically target tumor tissue, regardless of number and anatomical location, and we describe it as using low levels of radiation to illuminate tumor tissue and make it easier for the immune system to identify tumor tissue,' said researcher Weichert.
team has received $12.5 million from the National Cancer Institute to further develop treatments for multiple cancers.
Unlike traditional beam radiation therapy, which can be transported to all or most of the body's tissues in a non-targeted way, targeted radionuclide therapy mainly connects radioactive atoms (also known as radionuclides) to molecules that can be absorbed by tumor cells.
researcher Weichert et al. used a radioactive element and a special molecule to simulate a class of lipid molecules found in rapidly dividing cancer cells, while the researchers also used imaging techniques to make the drug's agents accurately injected into the body.
the researchers studied mice that combined immunotherapy targeted nuclein therapy was more powerful than using 1 alone, and then further investigated how a combination of different immunotherapy agents helped ward off cancer by avoiding the host immune system.
, for example, some cancer cells can find ways to shut down the immune cells that attack them, and researchers are now using immunosupger inhibitors to block the ability of cancer cells to target immune cells, ingesting immune cells, enough to have a chance to fight. Another study by
researchers focused on how immune cells themselves are activated, and researcher Professor Paul Sondel is working on an in situ vaccine that draws immune cells to tumors and activates them so that they can identify and kill cancer cells at tumor site, a technique that trains the immune system to retain memories of specific cancers in a manner similar to a vaccine against infectious diseases that directs the body's immune system to recognize pathogens such as bacteria and viruses.
The researchers now apply this collaborative approach to prostate cancer by combining the prostate tumor vaccine with targeted nucleotherapy, and they want to study whether targeted radiotherapy can first weaken the tumor, allowing stimulated immune cells to better perform the vaccine when attacking prostate cancer cells.
researchers liken these combination therapies to using bulldozers to destroy tumors, bulldozer ignition needs to be turned on, and in some cases, cancer vaccines can facilitate this process, bulldozers need fuel for power and acceleration, while the fuel provided by the drug can expand and multiply immune cells that attack cancer, and examine Point inhibitors can further speed up the process by lifting the brake on the immune system, and when multiple tumors are present, targeted radionuclide therapy can travel through the bloodstream to each tumor location in the body, which may promote the body's anti-tumor immune response and ultimately kill cancer cells throughout the body.
so far, researchers have studied a team of targeted radionuclide therapies and immunotherapy, hoping to expand their range of studies to include multiple types of therapies and use them alone or in combination to treat cancer.
Morris says the number of changes may become so large that we are not very clear about the interaction between these different therapies and their specific efficacy in treating patients; the only way to really understand these is to compare them experimentally in a strictly controlled way.
original source: A new way to help the immune system fight back against cancer by Kaine Korzekwa, University of Wisconsin-Madison Scientists at University of Wisconsin School of Medicine and Public Health is new to make cancer cells more susceptible to attack by the body's own immune system. Working in mice, a team led by Jamey Weichert, professor of radiology, and Zachary Morris, professor of human oncology, is combining two different techniques in its approach, using targeted radionuclide therapy, which delivers a low dose of cell-weakening radiation specifically to cancer cells, followed by immunotherapy, which helps the immune system to recognize and destroy cancer cells. The animal research is laying the foundation for future human and veterinary clinical trials. "This has a huge advantage because we can target tumors systemically, regardless of number and anatomic location," explains Weichert. "I often describe it as scuffing up the tumor with this low amount of radiation to make it easier for the immune system to recognize it." The team has been awarded $12.5 million in funding from the National Cancer Institute to further develop this approach to treating a variety of cancers, including prostate cancer and cancer in dogs......